Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Others

Ratios

NewAmsterdam Pharma (NAMS) Amortization of Deferred Charges (2025)

NewAmsterdam Pharma (NAMS) has disclosed Amortization of Deferred Charges for 1 consecutive years, with -$24000.0 as the latest value for Q4 2025.

Quarterly Amortization of Deferred Charges changed N/A to -$24000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.4 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$1.4 million for FY2025, 518.94% down from the prior year.
Amortization of Deferred Charges hit -$24000.0 in Q4 2025 for NewAmsterdam Pharma, up from -$396000.0 in the prior quarter.
In the past five years, Amortization of Deferred Charges ranged from a high of -$24000.0 in Q4 2025 to a low of -$513000.0 in Q1 2025.